Novel biological therapies for the treatment of diabetic foot ulcers

Jennifer Adeghate, Syed Nurulain, K. Tekes, E. Fehér, H. Kalász, Ernest Adeghate

Research output: Review article

8 Citations (Scopus)

Abstract

Introduction: The number of people with diabetes mellitus (DM) is estimated to exceed 640 million by the year 2040. Diabetic foot ulcer (DFU) is a debilitating illness that affects more than 2% of DM patients. DFU is caused by DM-induced neural and vascular lesions leading to a reduced sensation and microcirculation. The increase in the prevalence of DFU has prompted researchers to find new therapies for the management of DFU. Areas covered: This review presents the current status of novel biological therapies used in the treatment of DFU. Literature information and data analysis were collected from PubMed, the website of the American Diabetes Association, and ClinicalTrials.gov. The keywords used in the search were: DM, DFU, complications of DM. Expert opinion: Many biological agents have been investigated in a bid to find an effective therapy for DFU. These include growth factors (platelet-derived growth factor, vascular endothelial growth factor etc), stem cells (epithelial progenitor-, adipose-derived stem cells etc), anti-diabetic drugs (insulin, exendin-4), herbs, urokinase, dalteparin, statins and bio-agents such as acid peptide matrix. Biological agents that can reduce hyperglycaemia, increase sensation, microcirculation and oxygenation and repair lost tissue are the most ideal for the treatment of DFU.

Original languageEnglish
Pages (from-to)979-987
Number of pages9
JournalExpert Opinion on Biological Therapy
Volume17
Issue number8
DOIs
Publication statusPublished - aug. 3 2017

Fingerprint

Biological Therapy
Diabetic Foot
Medical problems
Microcirculation
Biological Factors
Diabetes Mellitus
Stem cells
Dalteparin
Therapeutics
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Information analysis
Oxygenation
Platelet-Derived Growth Factor
Urokinase-Type Plasminogen Activator
Stem Cells
Vascular Endothelial Growth Factor A
Websites
Repair
Hypesthesia
Insulin

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Novel biological therapies for the treatment of diabetic foot ulcers. / Adeghate, Jennifer; Nurulain, Syed; Tekes, K.; Fehér, E.; Kalász, H.; Adeghate, Ernest.

In: Expert Opinion on Biological Therapy, Vol. 17, No. 8, 03.08.2017, p. 979-987.

Research output: Review article

Adeghate, Jennifer ; Nurulain, Syed ; Tekes, K. ; Fehér, E. ; Kalász, H. ; Adeghate, Ernest. / Novel biological therapies for the treatment of diabetic foot ulcers. In: Expert Opinion on Biological Therapy. 2017 ; Vol. 17, No. 8. pp. 979-987.
@article{8cba6d0b333943a78def9d4c5f8ca99d,
title = "Novel biological therapies for the treatment of diabetic foot ulcers",
abstract = "Introduction: The number of people with diabetes mellitus (DM) is estimated to exceed 640 million by the year 2040. Diabetic foot ulcer (DFU) is a debilitating illness that affects more than 2{\%} of DM patients. DFU is caused by DM-induced neural and vascular lesions leading to a reduced sensation and microcirculation. The increase in the prevalence of DFU has prompted researchers to find new therapies for the management of DFU. Areas covered: This review presents the current status of novel biological therapies used in the treatment of DFU. Literature information and data analysis were collected from PubMed, the website of the American Diabetes Association, and ClinicalTrials.gov. The keywords used in the search were: DM, DFU, complications of DM. Expert opinion: Many biological agents have been investigated in a bid to find an effective therapy for DFU. These include growth factors (platelet-derived growth factor, vascular endothelial growth factor etc), stem cells (epithelial progenitor-, adipose-derived stem cells etc), anti-diabetic drugs (insulin, exendin-4), herbs, urokinase, dalteparin, statins and bio-agents such as acid peptide matrix. Biological agents that can reduce hyperglycaemia, increase sensation, microcirculation and oxygenation and repair lost tissue are the most ideal for the treatment of DFU.",
keywords = "Diabetes mellitus, diabetic angiopathy, diabetic foot, diabetic neuropathy, hyperglycemia, long-term complications, therapy, ulcer",
author = "Jennifer Adeghate and Syed Nurulain and K. Tekes and E. Feh{\'e}r and H. Kal{\'a}sz and Ernest Adeghate",
year = "2017",
month = "8",
day = "3",
doi = "10.1080/14712598.2017.1333596",
language = "English",
volume = "17",
pages = "979--987",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Novel biological therapies for the treatment of diabetic foot ulcers

AU - Adeghate, Jennifer

AU - Nurulain, Syed

AU - Tekes, K.

AU - Fehér, E.

AU - Kalász, H.

AU - Adeghate, Ernest

PY - 2017/8/3

Y1 - 2017/8/3

N2 - Introduction: The number of people with diabetes mellitus (DM) is estimated to exceed 640 million by the year 2040. Diabetic foot ulcer (DFU) is a debilitating illness that affects more than 2% of DM patients. DFU is caused by DM-induced neural and vascular lesions leading to a reduced sensation and microcirculation. The increase in the prevalence of DFU has prompted researchers to find new therapies for the management of DFU. Areas covered: This review presents the current status of novel biological therapies used in the treatment of DFU. Literature information and data analysis were collected from PubMed, the website of the American Diabetes Association, and ClinicalTrials.gov. The keywords used in the search were: DM, DFU, complications of DM. Expert opinion: Many biological agents have been investigated in a bid to find an effective therapy for DFU. These include growth factors (platelet-derived growth factor, vascular endothelial growth factor etc), stem cells (epithelial progenitor-, adipose-derived stem cells etc), anti-diabetic drugs (insulin, exendin-4), herbs, urokinase, dalteparin, statins and bio-agents such as acid peptide matrix. Biological agents that can reduce hyperglycaemia, increase sensation, microcirculation and oxygenation and repair lost tissue are the most ideal for the treatment of DFU.

AB - Introduction: The number of people with diabetes mellitus (DM) is estimated to exceed 640 million by the year 2040. Diabetic foot ulcer (DFU) is a debilitating illness that affects more than 2% of DM patients. DFU is caused by DM-induced neural and vascular lesions leading to a reduced sensation and microcirculation. The increase in the prevalence of DFU has prompted researchers to find new therapies for the management of DFU. Areas covered: This review presents the current status of novel biological therapies used in the treatment of DFU. Literature information and data analysis were collected from PubMed, the website of the American Diabetes Association, and ClinicalTrials.gov. The keywords used in the search were: DM, DFU, complications of DM. Expert opinion: Many biological agents have been investigated in a bid to find an effective therapy for DFU. These include growth factors (platelet-derived growth factor, vascular endothelial growth factor etc), stem cells (epithelial progenitor-, adipose-derived stem cells etc), anti-diabetic drugs (insulin, exendin-4), herbs, urokinase, dalteparin, statins and bio-agents such as acid peptide matrix. Biological agents that can reduce hyperglycaemia, increase sensation, microcirculation and oxygenation and repair lost tissue are the most ideal for the treatment of DFU.

KW - Diabetes mellitus

KW - diabetic angiopathy

KW - diabetic foot

KW - diabetic neuropathy

KW - hyperglycemia

KW - long-term complications

KW - therapy

KW - ulcer

UR - http://www.scopus.com/inward/record.url?scp=85023614392&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85023614392&partnerID=8YFLogxK

U2 - 10.1080/14712598.2017.1333596

DO - 10.1080/14712598.2017.1333596

M3 - Review article

VL - 17

SP - 979

EP - 987

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 8

ER -